▶주메뉴 바로가기

▶본문 바로가기

THE INVESTOR
March 26, 2019
Big Reunion

Bio & Medicine

Handok Pharma, Genexine purchase US bio firm

  • PUBLISHED :January 08, 2019 - 15:02
  • UPDATED :January 08, 2019 - 15:02
  • 폰트작게
  • 폰트크게
  • facebook
  • twitter
  • sms
  • print


[THE INVESTOR] Korean firm Handok Pharmaceuticals said on Jan. 8 that it has entered a US$25 million preferred stock purchase agreement with local player Genexine to invest in an American drug maker.

The arrangement allows the two companies to purchase a combined 54 percent share of Rezolute, a clinical stage biopharmaceutical company, officials said.


Handok said the purchase is a strategic investment as the company aims to make further inroads into the world’s largest biopharma market.

“We believe the purchase will play a bigger role for us to make a headway in the United States,” Handok CEO Kim Young-jin said in a press release.

Rezolute, established in 2010, specializes in the development of medication to fight metabolic and orphan diseases.

By Song Seung-hyun and newswires (ssh@heraldcorp.com)

  • facebook
  • twitter
  • sms
  • print

EDITOR'S PICKS